GE continues to increase its investment in personalized medicine , and its interest in using genetic information to provide individualized care for patients is growing. The big group is currently acquiring SeqWright, a contract sequencing company in Houston – the purchase price is not public.
As pharmaceutical companies develop more and more targeted therapies for a variety of diseases, such as cancer, doctors need to know more about the specific biological characteristics of different cancers in order to find more effective treatment options.
And this is where GE wants to enter, by developing technology to better understand the genetic characteristics of cancer and other diseases. Last year, GE announced that it would invest $1 billion over the next five years to research and develop advanced cancer diagnostics and molecular imaging capabilities, as well as to produce biopharmaceuticals.
Two years ago, GE invested $580 million in cancer research company Clarient to fund its expansion into molecular diagnostics. GE said that SeqWright will provide a deeper genetic sequencing analysis through its own capabilities to evaluate a large number of genetic material.
Carrie Eglinton-Manner, CEO of Clarient, said the deal would "strengthen the services we provide to pharmaceutical companies."
SeqWright will continue its contract work with pharmaceutical companies such as Lilly and Roche. These companies use its technology to identify mutations associated with a range of diseases ranging from mental illness to heart disease. SeqWright also collaborated with the US Department of Agriculture to map the complete coding sequences of 150 different influenza virus variants.
Printing Blister Card Mask Packaging
printing blister card N95 mask Packaging individual package
Face Mask Packaging,Blister Card Packaging,Custom Retail Packaging,Printed Retail Packaging
taicang hexiang packaging material co.,ltd , https://www.medpackhexiang.com